2 March 2021
Davis Polk advised the representatives of the underwriters on the $177 million SEC-registered follow-on secondary offering of 3,283,950 American depositary shares, each 10 ADSs representing 23 ordinary shares, by certain selling shareholders of I-Mab. On February 26, 2021, the underwriters exercised the option to purchase an additional 492,590 ADSs from certain selling shareholders. The ADSs are listed on the Nasdaq Global Market under the symbol “IMAB”.
I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab has developed an innovative pipeline of more than 10 clinical and pre-clinical stage assets through its internal research and development efforts and in-licensing arrangements with global pharmaceutical and biotech companies.
The Davis Polk corporate team included partners Li He and James C. Lin, counsel Xuelin (Steve) Wang and registered foreign lawyer Jennifer Liu. Counsel Alon Gurfinkel and associate Summer Xia provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Hong Kong, London and New York offices.
